{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:53:06Z","timestamp":1761519186239},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T00:00:00Z","timestamp":1487808000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ejca.2017.02.011","type":"journal-article","created":{"date-parts":[[2017,3,27]],"date-time":"2017-03-27T23:16:58Z","timestamp":1490656618000},"page":"205-215","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial"],"prefix":"10.1016","volume":"76","author":[{"given":"Chris","family":"Twelves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce","family":"O'Shaughnessy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Awada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith A.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seock\u2013Ah","family":"Im","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"G\u00f3mez-Pardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee S.","family":"Schwartzberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Di\u00e9ras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise A.","family":"Yardley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Potter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Mailliez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvaro","family":"Moreno-Aspitia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Seok","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Hoch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison L.","family":"Hannah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hope S.","family":"Rugo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejca.2017.02.011_bib1","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1177\/1758834013508197","article-title":"Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians","volume":"5","author":"Palumbo","year":"2013","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2017.02.011_bib2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s11864-012-0184-6","article-title":"Chemotherapy-resistant metastatic breast cancer","volume":"13","author":"Marquette","year":"2012","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2017.02.011_bib3","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1200\/JCO.2010.30.2174","article-title":"How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials","volume":"29","author":"Kiely","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.02.011_bib4","unstructured":"World Health Organization. WHO Cancer factsheet N\u00b0 297. Updated February 2015. Available at: http:\/\/www.who.int\/mediacentre\/factsheets\/fs297\/en\/index.html. [Accessed 4 February 2015]."},{"key":"10.1016\/j.ejca.2017.02.011_bib5","series-title":"GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]","author":"Ferlay","year":"2013"},{"key":"10.1016\/j.ejca.2017.02.011_bib6","first-page":"307","article-title":"Breast cancer brain metastases: new directions in systemic therapy","volume":"7","author":"Lin","year":"2013","journal-title":"Ecancermedicalscience"},{"issue":"Suppl. 6","key":"10.1016\/j.ejca.2017.02.011_bib7","doi-asserted-by":"crossref","first-page":"vi46","DOI":"10.1093\/annonc\/mds195","article-title":"Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents","volume":"23","author":"Andr\u00e9","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2017.02.011_bib8","first-page":"79","article-title":"Emerging role of brain metastases in the prognosis of breast cancer patients","volume":"3","author":"Hambrecht","year":"2011","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.011_bib9","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1517\/14656560902834961","article-title":"Therapeutic options for metastatic breast cancer","volume":"10","author":"Morris","year":"2009","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.011_bib10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1634\/theoncologist.9-6-617","article-title":"Facts and controversies in systemic treatment of metastatic breast cancer","volume":"9","author":"Bernard-Marty","year":"2004","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ejca.2017.02.011_bib11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/1758834010395342","article-title":"Health-related quality of life and cancer clinical trials","volume":"3","author":"Osoba","year":"2012","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2017.02.011_bib12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/jncimonographs\/lgm010","article-title":"Health-related quality of life measurement in symptom management trials","volume":"37","author":"Ganz","year":"2007","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"8","key":"10.1016\/j.ejca.2017.02.011_bib13","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1200\/JCO.2011.38.5161","article-title":"American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care","volume":"30","author":"Smith","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.02.011_bib14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jnci\/djq508","article-title":"Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001\u20132009)","volume":"103","author":"Lemieux","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2017.02.011_bib15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1477-7525-8-89","article-title":"Patient reported outcomes: looking beyond the label","volume":"8","author":"Doward","year":"2010","journal-title":"Health Qual Life Outcomes"},{"issue":"15","key":"10.1016\/j.ejca.2017.02.011_bib16","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/S1470-2045(15)00332-0","article-title":"Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracyline- taxane- and capecitabine (BEACON): a randomized, open-label, multicenter, phase 3 trial","volume":"16","author":"Perez","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.011_bib17","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s00280-014-2577-7","article-title":"Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models","volume":"74","author":"Hoch","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.011_bib18","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1158\/1078-0432.CCR-12-1201","article-title":"Multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors","volume":"19","author":"Jameson","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2017.02.011_bib19","article-title":"First phase 1 trial of NKTR-102 (peg-irinotecan) reveals early evidence of broad antitumor activity in three different schedules","volume":"6","author":"Von Hoff","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2017.02.011_bib20","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1023\/A:1013157727506","article-title":"Phase 1 dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks","volume":"12","author":"Rothenberg","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2017.02.011_bib21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2017.02.011_bib22","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1200\/JCO.1996.14.10.2756","article-title":"The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study","volume":"14","author":"Sprangers","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.02.011_bib23","series-title":"The EORTC QLQ-C30 scoring manual","author":"Fayers","year":"2001"},{"key":"10.1016\/j.ejca.2017.02.011_bib24","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0006-3223(02)01867-X","article-title":"Assessing and interpreting treatment effects in longitudinal clinical trials with missing data","volume":"53","author":"Mallinckrodt","year":"2003","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.ejca.2017.02.011_bib25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1081\/BIP-100104194","article-title":"Accounting for dropout bias using mixed-effects models","volume":"11","author":"Mallinckrodt","year":"2001","journal-title":"J Biopharm Stat"},{"key":"10.1016\/j.ejca.2017.02.011_bib26","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2307\/2531734","article-title":"Models for longitudinal data: a generalized estimating equation approach","volume":"44","author":"Zeger","year":"1988","journal-title":"Biometrics"},{"key":"10.1016\/j.ejca.2017.02.011_bib27","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/S1470-2045(13)70429-7","article-title":"Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study","volume":"14","author":"Awada","year":"2013","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917307360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917307360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T12:40:54Z","timestamp":1601815254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917307360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":27,"alternative-id":["S0959804917307360"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.02.011","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}